Antibody-Based Treatment Approaches in Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• The treatment landscape for multiple myeloma is rapidly evolving.
• Antibody-based therapies represent a significant advancement in clinical practice.

Purpose of the Study:

• To review the clinical applications of antibody-based modalities in multiple myeloma.
• Focus on monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies.

Main Methods:

• Review of recent clinical practice and FDA-approved antibody-based treatments.
• Analysis of ongoing clinical trials for novel targets and antibody constructs.
• Examination of strategies to overcome therapeutic resistance.

Main Results:

• Three monoclonal antibodies and one anti-BCMA antibody-drug conjugate are FDA-approved.
• Numerous clinical trials are investigating new targets (BCMA, GPRC5D, FCRH5) and bispecific antibodies.
• Antibody-based therapies have improved patient outcomes and are integrated into standard care.

Conclusions:

• Antibody-based therapies have transformed multiple myeloma treatment, improving outcomes.
• Future research will focus on novel targets, enhanced durability, and minimized toxicity.
• Expect wider application of antibody strategies in earlier treatment lines.